Gerrina Ruiter, MD, PhD, on Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Baseline Brain Metastases
IASLC WCLC 2025
Gerrina Ruiter, MD, PhD, of the Netherlands Cancer Institute, discusses data from the Beamion LUNG-1 trial, which is evaluating zongertinib—an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing EGFR—in patients with HER2-mutant advanced or metastatic non–small cell lung cancer (NSCLC). This analysis of the trial focused on previously treated patients with active brain metastases (cohort 4) or stable/asymptomatic brain metastases (cohort 1) at baseline (Abstract PT2.12.03).
The ASCO Post Staff
David Gerber, MD, of UT Southwestern Medical Center, reviews findings from the phase III E4512 trial, which evaluated the hypothesis that postoperative crizotinib may improve disease-free survival in patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), based on the drug’s efficacy and regulatory approval in advanced ALK-positive NSCLC (Abstract PL02.18).
The ASCO Post Staff
John M. Varlotto, MD, presents results from the phase III EA5181 trial (from the ECOG-ACRIN Cancer Research Group), which evaluated concurrent and consolidation durvalumab vs consolidation durvalumab alone for patients with unresectable stage III non–small cell lung cancer (NSCLC) (Abstract PL03.04).
The ASCO Post Staff
Jordi Remon, MD, PhD, of Gustave Roussy, was the invited discussant for the phase III ACROSS 2 study (Abstract PL02.06). Dr. Remon describes the effect of the addition of aumolertinib, an oral third-generation EGFR tyrosine kinase inhibitor, to platinum/pemetrexed chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor-suppressor gene mutations.
The ASCO Post Staff
Susan C. Scott, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presents findings from cohort 5 of the phase II PALOMA-2 trial. The data show that subcutaneous administration of the bispecific monoclonal antibody amivantamab-vmjw every 4 weeks, combined with daily receipt of the EGFR TKI lazertinib orally, resulted in high objective response rates among patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract MA08.05).
The ASCO Post Staff
Jonathan D. Spicer, MD, PhD, of McGill University Health Centre, discusses health-related quality of life (HRQoL) findings from the CheckMate 77T trial. The analysis determined that receipt of perioperative nivolumab does not result in worse HRQoL outcomes vs placebo in patients with resectable non–small cell lung cancer (NSCLC), regardless of nodal status (Abstract MA04.05).
